These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 28677529)

  • 41. FACS-Assisted CRISPR-Cas9 Genome Editing Facilitates Parkinson's Disease Modeling.
    Arias-Fuenzalida J; Jarazo J; Qing X; Walter J; Gomez-Giro G; Nickels SL; Zaehres H; Schöler HR; Schwamborn JC
    Stem Cell Reports; 2017 Nov; 9(5):1423-1431. PubMed ID: 28988985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Generation of two tdTomato reporter induced pluripotent stem cell lines (NHLBIi003-A-1 and NHLBIi003-A-2) by AAVS1 safe harbor gene-editing.
    Patterson K; Linask KL; Beers J; Zou J
    Stem Cell Res; 2020 Jan; 42():101673. PubMed ID: 31869686
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges.
    Demirci S; Leonard A; Haro-Mora JJ; Uchida N; Tisdale JF
    Adv Exp Med Biol; 2019; 1144():37-52. PubMed ID: 30715679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Generation of AAVS1 integrated doxycycline-inducible CRISPR-Prime Editor human induced pluripotent stem cell line.
    Bharucha N; Ataam JA; Gavidia AA; Karakikes I
    Stem Cell Res; 2021 Dec; 57():102610. PubMed ID: 34875545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generating autologous hematopoietic cells from human-induced pluripotent stem cells through ectopic expression of transcription factors.
    Hwang Y; Broxmeyer HE; Lee MR
    Curr Opin Hematol; 2017 Jul; 24(4):283-288. PubMed ID: 28383341
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Generation of a CAG-EGFP tagged cell line (KSCBi017-A-2) from human induced pluripotent stem cells using CRISPR/Cas9.
    Han HW; Im YS; Kim YO; Kwak S; Cho SJ
    Stem Cell Res; 2024 Mar; 75():103303. PubMed ID: 38211411
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Generation of a human extended pluripotent stem cell line (SKLRMe002-A) carrying a doxycycline-inducible Cas9 expression cassette.
    He Z; Feng K; Sun H; Yu T; Zhu D; Yang Y
    Stem Cell Res; 2022 Jul; 62():102816. PubMed ID: 35617843
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Scaled Framework for CRISPR Editing of Human Pluripotent Stem Cells to Study Psychiatric Disease.
    Hazelbaker DZ; Beccard A; Bara AM; Dabkowski N; Messana A; Mazzucato P; Lam D; Manning D; Eggan K; Barrett LE
    Stem Cell Reports; 2017 Oct; 9(4):1315-1327. PubMed ID: 29020615
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Generation of Monoclonal iPSC Lines with Stable Cas9 Expression and High Cas9 Activity.
    Liao JQ; Zhou G; Zhou Y
    Methods Mol Biol; 2022; 2454():575-588. PubMed ID: 32567018
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Generation of a gene edited hemophilia A patient-derived iPSC cell line, YCMi001-B-1, by targeted insertion of coagulation factor FVIII using CRISPR/Cas9.
    Sung JJ; Park S; Choi SH; Kim J; Cho MS; Kim DW
    Stem Cell Res; 2020 Oct; 48():101948. PubMed ID: 32798916
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Step-Wise Chondrogenesis of Human Induced Pluripotent Stem Cells and Purification Via a Reporter Allele Generated by CRISPR-Cas9 Genome Editing.
    Adkar SS; Wu CL; Willard VP; Dicks A; Ettyreddy A; Steward N; Bhutani N; Gersbach CA; Guilak F
    Stem Cells; 2019 Jan; 37(1):65-76. PubMed ID: 30378731
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Homozygous might be hemizygous: CRISPR/Cas9 editing in iPSCs results in detrimental on-target defects that escape standard quality controls.
    Simkin D; Papakis V; Bustos BI; Ambrosi CM; Ryan SJ; Baru V; Williams LA; Dempsey GT; McManus OB; Landers JE; Lubbe SJ; George AL; Kiskinis E
    Stem Cell Reports; 2022 Apr; 17(4):993-1008. PubMed ID: 35276091
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CRISPR/Cas-Mediated Knock-in of Genetically Encoded Fluorescent Biosensors into the AAVS1 Locus of Human-Induced Pluripotent Stem Cells.
    Stellon D; Tran MTN; Talbot J; Chear S; Khalid MKNM; Pébay A; Vickers JC; King AE; Hewitt AW; Cook AL
    Methods Mol Biol; 2022; 2549():379-398. PubMed ID: 34505269
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Generation of a TLR7 homozygous knockout human induced pluripotent stem cell line using CRISPR/Cas9.
    Han HJ; Seo HH; Han HW; Kim JH
    Stem Cell Res; 2019 Oct; 40():101520. PubMed ID: 31445394
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Impact of Chromatin Dynamics on Cas9-Mediated Genome Editing in Human Cells.
    Daer RM; Cutts JP; Brafman DA; Haynes KA
    ACS Synth Biol; 2017 Mar; 6(3):428-438. PubMed ID: 27783893
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish.
    Hruscha A; Krawitz P; Rechenberg A; Heinrich V; Hecht J; Haass C; Schmid B
    Development; 2013 Dec; 140(24):4982-7. PubMed ID: 24257628
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Generation of a PXR reporter human induced pluripotent stem cell line (PXR-mCherry hiPSC) using the CRISPR/Cas9 system.
    Kim H; Kim JW; Kim SJ; Choi YJ; Kim DS; Park HJ
    Stem Cell Res; 2018 Jan; 26():72-75. PubMed ID: 29247817
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Engineering the AAVS1 locus for consistent and scalable transgene expression in human iPSCs and their differentiated derivatives.
    Oceguera-Yanez F; Kim SI; Matsumoto T; Tan GW; Xiang L; Hatani T; Kondo T; Ikeya M; Yoshida Y; Inoue H; Woltjen K
    Methods; 2016 May; 101():43-55. PubMed ID: 26707206
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Generation and validation of PAX7 reporter lines from human iPS cells using CRISPR/Cas9 technology.
    Wu J; Hunt SD; Xue H; Liu Y; Darabi R
    Stem Cell Res; 2016 Mar; 16(2):220-8. PubMed ID: 26826926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation.
    Huang X; Wang Y; Yan W; Smith C; Ye Z; Wang J; Gao Y; Mendelsohn L; Cheng L
    Stem Cells; 2015 May; 33(5):1470-9. PubMed ID: 25702619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.